Pfizer INC Schedule 13D activist filings

Pfizer Inc. reported a decrease in its beneficial ownership of Allogene Therapeutics, Inc. common stock to 9.0%, solely due to an increase in Allogene's outstanding shares.

Pfizer Inc. has announced the completion of its divestment from Haleon plc, ceasing to be a beneficial owner of the consumer healthcare company's shares following a secondary offering and a share buyback.

Pfizer Inc. has announced the final divestment of its entire 7.3% beneficial ownership in Haleon plc through a secondary block trade offering of 617.55 million shares and a concurrent share buyback by Haleon of 44 million shares, totaling approximately $220 million.

Pfizer Inc. filed an Amendment No. 13 to its Schedule 13D, disclosing its continued beneficial ownership of 7.3% of Haleon plc's Ordinary Shares and the departure of its nominated director, Mr. Supran, following the termination of the Pfizer Relationship Agreement.

Pfizer Inc. has significantly reduced its beneficial ownership in Haleon plc to approximately 7.3% after completing a secondary offering of 700 million Ordinary Shares, generating substantial proceeds.

Pfizer Inc. announced an amendment to its Schedule 13D, detailing a secondary offering of 700 million Haleon plc Ordinary Shares, which will reduce its beneficial ownership to less than 10% and terminate its contractual right to nominate directors to Haleon's Board.